-+ 0.00%
-+ 0.00%
-+ 0.00%

Ling Rui Pharmaceutical announced that the company recently received the “Drug Registration Certificate” for flubiprofen gel paste approved and issued by the State Drug Administration. This drug is a topical non-steroidal anti-inflammatory drug. It is a Class 4 chemical drug and a Class B type of national medical insurance. It has analgesic and anti-inflammatory effects, and is suitable for various painful swelling conditions such as osteoarthritis and periodontitis. Up to now, the company has invested about 35.43 million yuan in research and development of this drug. Obtaining a registration certificate this time will enrich the company's topical patch product line. This product is regarded as having passed a consistent evaluation of the quality and efficacy of generic drugs, which is expected to have a positive impact on the company's operations.

Zhitongcaijing·11/16/2026 08:41:16
Listen to the news
Ling Rui Pharmaceutical announced that the company recently received the “Drug Registration Certificate” for flubiprofen gel paste approved and issued by the State Drug Administration. This drug is a topical non-steroidal anti-inflammatory drug. It is a Class 4 chemical drug and a Class B type of national medical insurance. It has analgesic and anti-inflammatory effects, and is suitable for various painful swelling conditions such as osteoarthritis and periodontitis. Up to now, the company has invested about 35.43 million yuan in research and development of this drug. Obtaining a registration certificate this time will enrich the company's topical patch product line. This product is regarded as having passed a consistent evaluation of the quality and efficacy of generic drugs, which is expected to have a positive impact on the company's operations.